NA-Semax Amidate
N-Acetyl Semax Amidate · NASA
Popular for:Enhanced cognitive version of Semax, longer-acting, BDNF stimulation
0
Total Studies
0
Human Studies
Approved
Evidence Level
Not Approved
FDA Status
Overview
NA-Semax Amidate (N-Acetyl Semax Amidate) is a modified version of the Russian nootropic peptide Semax, with two chemical modifications: an N-terminal acetyl group and a C-terminal amide group. These modifications increase the peptide's stability, bioavailability, and duration of action compared to standard Semax.
The acetylation protects against aminopeptidase degradation while the amidation protects against carboxypeptidase degradation, effectively shielding both ends of the peptide from enzymatic breakdown. This results in a longer-acting and more potent version that has become the preferred form in the Western research peptide community.
Mechanism of Action
Like standard Semax, NA-Semax Amidate is a synthetic analog of ACTH (4-10) that stimulates BDNF (Brain-Derived Neurotrophic Factor) and NGF (Nerve Growth Factor) expression. It modulates serotonergic, dopaminergic, and cholinergic neurotransmitter systems. The enhanced stability from the acetyl and amide modifications means higher effective concentrations reach target neural tissues, potentially producing stronger neurotrophic effects per dose compared to standard Semax.
Key Research Benefits
Clinical Evidence Summary
Research Pipeline
International Regulatory Status
Cognitive disorders (approved as parent compound Semax)
Source0
Total Studies
0
Human Studies
Not FDA-approved. Modified version of Russian-approved Semax. Research compound. Popular in nootropics community as the preferred Semax variant.
Key Studies / PubMed References
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
ReviewRahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026
PMID: 41490200Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
Animal StudyLiu R, Chen Y, Huang H, et al. · British journal of pharmacology · 2025
PMID: 40692165ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke.
Animal StudyFilippenkov IB, Shpetko YY, Stavchansky VV, et al. · Biomedicines · 2024
PMID: 39767736[The efficacy of semax in the tretament of patients at different stages of ischemic stroke].
Human StudyGusev EI, Martynov MY, Kostenko EV, et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2018
PMID: 29798983Pharmacological Aspects of Neuro-Immune Interactions.
ReviewTarasov VV, Kudryashov NV, Chubarev VN, et al. · Current pharmaceutical design · 2018
PMID: 28875850Side Effects & Safety
Known Interactions
No curated interaction entry is live for NA-Semax Amidate yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. NA-Semax Amidate is not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before making any health-related decisions. The studies referenced are linked to their original PubMed sources for verification.